The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome.
BACKGROUND
Inflammation promotes acute coronary syndromes (ACS) and ensuing clinical complications. It is well known that statins decrease the risk of coronary events and may benefit the stabilization of atherosclerotic plaque with their anti-inflammatory effects. We investigated the effects of different doses of fluvastatin on serum concentrations of high-sensitive C-reaction protein (hs-CRP) and tumor necrosis factor-alpha (TNF-alpha) in the early phase of ACS.


METHODS
We prospectively randomized 60 patients with ACS to 3 groups: (1) group A (n=20): were given routine therapy; (2) group B (n=20): were administrated routine therapy with 40 mg/d oral fluvastatin; (3) group C (n=20): received routine therapy with 80 mg/d oral fluvastatin. Twenty patients with stable coronary heart disease served as controls. The following-up period was 7 days. By immunoturbidimetric assay and ELISA methods the serum concentrations of hs-CRP and TNF-alpha were measured before and after therapy.


RESULTS
(1) The serum concentrations of hs-CRP and TNF-alpha in patients with ACS was significantly higher than those in the control group (P<0.05). (2) After 1 week of therapy, the serum concentrations of hs-CRP and TNF-alpha were significantly lower in group B and group C (all P<0.01), especially in group C. (3) The serum concentrations of hs-CRP and TNF-alpha did not correlate to the concentrations of TC, TG, LDL-C, or HDL-C.


CONCLUSIONS
Early fluvastatin intervention decreases dose-dependently the serum concentrations of hs-CRP and TNF-alpha of patients with ACS. The high-dose fluvastatin invention may play a stronger anti-inflammatory effect in ACS patients. The anti-inflammatory effect of fluvastatin may be beyond the lipid lowering.
Yang
Jun
J
Department of Cardiology, Second Xiangya Hospital of Central South University, Middle Ren-Min road No.86, Changsha, Hunan 410011, PR China. yangj523@hotmail.com
Li
Xiang-Ping
XP
Zhao
Shui-Ping
SP
Li
Jiang
J
Li
Jing-Dong
JD
Xie
Xiao-Ming
XM
D000208:Acute Disease; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D003327:Coronary Disease / Q000097:blood* / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage* / Q000627:therapeutic use*; D005260:Female; D000077340:Fluvastatin; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000097:blood*; D050356:Lipid Metabolism / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D013577:Syndrome; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D015415:Biomarkers; D005229:Fatty Acids, Monounsaturated; D007211:Indoles; D018836:Inflammation Mediators; D014409:Tumor Necrosis Factor-alpha; D000077340:Fluvastatin; D002097:C-Reactive Protein